Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Total Non-Current Liabilities: 2024-2025

Historic Total Non-Current Liabilities for Crinetics Pharmaceuticals (CRNX) over the last 2 years, with Sep 2025 value amounting to $121.0 million.

  • Crinetics Pharmaceuticals' Total Non-Current Liabilities rose 16.45% to $121.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.0 million, marking a year-over-year increase of 16.45%. This contributed to the annual value of $109.0 million for FY2024, which is N/A change from last year.
  • As of Q3 2025, Crinetics Pharmaceuticals' Total Non-Current Liabilities stood at $121.0 million, which was up 4.54% from $115.7 million recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Total Non-Current Liabilities ranged from a high of $121.0 million in Q3 2025 and a low of $103.9 million during Q3 2024.
  • For the 2-year period, Crinetics Pharmaceuticals' Total Non-Current Liabilities averaged around $109.9 million, with its median value being $107.3 million (2024).
  • Data for Crinetics Pharmaceuticals' Total Non-Current Liabilities shows a peak YoY rose of 16.45% (in 2025) over the last 5 years.
  • Crinetics Pharmaceuticals' Total Non-Current Liabilities (Quarterly) stood at $109.0 million in 2024, then climbed by 16.45% to $121.0 million in 2025.
  • Its Total Non-Current Liabilities stands at $121.0 million for Q3 2025, versus $115.7 million for Q2 2025 and $105.6 million for Q1 2025.